368 related articles for article (PubMed ID: 33368875)
1. Personalized cancer vaccination in head and neck cancer.
Shibata H; Zhou L; Xu N; Egloff AM; Uppaluri R
Cancer Sci; 2021 Mar; 112(3):978-988. PubMed ID: 33368875
[TBL] [Abstract][Full Text] [Related]
2. Breaking Ground in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Novel Therapies Beyond PD-L1 Immunotherapy.
Rosenberg AJ; Perez CA; Guo W; de Oliveira Novaes JM; da Silva Reis KFO; McGarrah PW; Price KAR
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e433330. PubMed ID: 38718318
[TBL] [Abstract][Full Text] [Related]
3. Computational Prediction and Validation of Tumor-Associated Neoantigens.
Roudko V; Greenbaum B; Bhardwaj N
Front Immunol; 2020; 11():27. PubMed ID: 32117226
[TBL] [Abstract][Full Text] [Related]
4. Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck Cancer.
Solis RN; Silverman DA; Birkeland AC
Curr Treat Options Oncol; 2022 Feb; 23(2):254-267. PubMed ID: 35195839
[TBL] [Abstract][Full Text] [Related]
5. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
Kiyotani K; Chan HT; Nakamura Y
Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513
[TBL] [Abstract][Full Text] [Related]
6. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
[TBL] [Abstract][Full Text] [Related]
7. Personalized cancer vaccines: adjuvants are important, too.
Gouttefangeas C; Rammensee HG
Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
[TBL] [Abstract][Full Text] [Related]
8. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine.
Noguchi M; Sasada T; Itoh K
Cancer Immunol Immunother; 2013 May; 62(5):919-29. PubMed ID: 23197273
[TBL] [Abstract][Full Text] [Related]
9. Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group.
De Mattos-Arruda L; Vazquez M; Finotello F; Lepore R; Porta E; Hundal J; Amengual-Rigo P; Ng CKY; Valencia A; Carrillo J; Chan TA; Guallar V; McGranahan N; Blanco J; Griffith M
Ann Oncol; 2020 Aug; 31(8):978-990. PubMed ID: 32610166
[TBL] [Abstract][Full Text] [Related]
10. Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments.
Jayawickrama SM; Ranaweera PM; Pradeep RGGR; Jayasinghe YA; Senevirathna K; Hilmi AJ; Rajapakse RMG; Kanmodi KK; Jayasinghe RD
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2045. PubMed ID: 38522008
[TBL] [Abstract][Full Text] [Related]
11. Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma.
Ludwig S; Hong CS; Razzo BM; Fabian KPL; Chelvanambi M; Lang S; Storkus WJ; Whiteside TL
Cancer Immunol Immunother; 2019 Jul; 68(7):1133-1141. PubMed ID: 31139925
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant immunotherapy for head and neck squamous cell carcinoma.
Kürten CHL; Ferris RL
Laryngorhinootologie; 2024 May; 103(S 01):S167-S187. PubMed ID: 38697147
[TBL] [Abstract][Full Text] [Related]
13. mRNA-based precision targeting of neoantigens and tumor-associated antigens in malignant brain tumors.
Trivedi V; Yang C; Klippel K; Yegorov O; von Roemeling C; Hoang-Minh L; Fenton G; Ogando-Rivas E; Castillo P; Moore G; Long-James K; Dyson K; Doonan B; Flores C; Mitchell DA
Genome Med; 2024 Jan; 16(1):17. PubMed ID: 38268001
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
Bauman JE; Cohen E; Ferris RL; Adelstein DJ; Brizel DM; Ridge JA; O'Sullivan B; Burtness BA; Butterfield LH; Carson WE; Disis ML; Fox BA; Gajewski TF; Gillison ML; Hodge JW; Le QT; Raben D; Strome SE; Lynn J; Malik S
Cancer; 2017 Apr; 123(7):1259-1271. PubMed ID: 27906454
[TBL] [Abstract][Full Text] [Related]
15. Neoantigen cancer vaccines: a new star on the horizon.
Li X; You J; Hong L; Liu W; Guo P; Hao X
Cancer Biol Med; 2023 Dec; 21(4):274-311. PubMed ID: 38164734
[TBL] [Abstract][Full Text] [Related]
16. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer.
Hu C; Liu M; Li Y; Zhao Y; Sharma A; Liu H; Schmidt-Wolf IGH
Front Immunol; 2023; 14():1213716. PubMed ID: 37457699
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in personalized cancer immunotherapy with immune checkpoint inhibitors, T cells and vaccines.
Faghfuri E
Per Med; 2024 Jan; 21(1):45-57. PubMed ID: 38088165
[TBL] [Abstract][Full Text] [Related]
18. Head and neck cancer treatment in the era of molecular medicine.
Pandruvada S; Kessler R; Thai A
Adv Cancer Res; 2023; 160():205-252. PubMed ID: 37704289
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Derived Antigenic Peptides as Potential Cancer Vaccines.
Sotirov S; Dimitrov I
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732150
[TBL] [Abstract][Full Text] [Related]
20. Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
Whiteside TL
Clin Cancer Res; 2018 Jan; 24(1):6-13. PubMed ID: 28751445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
